Abbott Laboratories Dirección

Dirección controles de criterios 3/4

El CEO de Abbott Laboratories es Robert Ford , nombrado en Oct 2018, tiene una permanencia de 6.08 años. compensación anual total es $23.27M, compuesta por 6.4% salario y 93.6% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.024% de las acciones de la empresa, por valor de ARS49.08B. La antigüedad media del equipo directivo y de la junta directiva es de 5.8 años y 5.8 años, respectivamente.

Información clave

Robert Ford

Chief Executive Officer (CEO)

US$23.3m

Compensación total

Porcentaje del salario del CEO	6.4%
Permanencia del CEO	6.1yrs
Participación del CEO	0.02%
Permanencia media de la dirección	5.8yrs
Promedio de permanencia en la Junta Directiva	5.8yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Robert Ford en comparación con los beneficios de Abbott Laboratories?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2024	n/a	n/a	US$6b
Jun 30 2024	n/a	n/a	US$6b
Mar 31 2024	n/a	n/a	US$6b
Dec 31 2023	US$23m	US$2m	US$6b
Sep 30 2023	n/a	n/a	US$5b
Jun 30 2023	n/a	n/a	US$5b
Mar 31 2023	n/a	n/a	US$6b
Dec 31 2022	US$22m	US$2m	US$7b
Sep 30 2022	n/a	n/a	US$8b
Jun 30 2022	n/a	n/a	US$9b
Mar 31 2022	n/a	n/a	US$8b
Dec 31 2021	US$25m	US$1m	US$7b
Sep 30 2021	n/a	n/a	US$7b
Jun 30 2021	n/a	n/a	US$6b
Mar 31 2021	n/a	n/a	US$6b
Dec 31 2020	US$20m	US$1m	US$4b
Sep 30 2020	n/a	n/a	US$3b
Jun 30 2020	n/a	n/a	US$3b
Mar 31 2020	n/a	n/a	US$4b
Dec 31 2019	US$12m	US$1m	US$4b
Sep 30 2019	n/a	n/a	US$3b
Jun 30 2019	n/a	n/a	US$3b
Mar 31 2019	n/a	n/a	US$3b
Dec 31 2018	US$8m	US$784k	US$2b
Sep 30 2018	n/a	n/a	US$802m
Jun 30 2018	n/a	n/a	US$812m
Mar 31 2018	n/a	n/a	US$365m
Dec 31 2017	US$5m	US$675k	US$344m

Compensación vs. Mercado: La compensación total de Robert($USD23.27M) está por encima de la media de empresas de tamaño similar en el mercado AR ($USD5.73M).

Compensación vs. Ingresos: La compensación de Robert ha sido consistente con los resultados de la empresa en el último año.

CEO

Robert Ford (50 yo)

6.1yrs

Permanencia

US$23,268,171

Compensación

Mr. Robert B. Ford has been the Chief Executive Officer of Abbott Laboratories since March 31, 2020 and also serves as its Chairman of the Board since December 10, 2021. He has been President at Abbott Lab...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Robert Ford	Chairman of the Board	6.1yrs	US$23.27m	0.024% ARS 49.1b
Philip Boudreau	CFO & Executive VP of Finance	1.2yrs	US$3.32m	0.0023% ARS 4.6b
Hubert Allen	Executive VP	11.8yrs	US$7.42m	0.011% ARS 21.7b
Daniel Salvadori	Executive VP and Group President of Established Pharmaceuticals & Nutritional Products	10.2yrs	US$5.93m	0.0073% ARS 14.8b
Lisa Earnhardt	Executive VP & Group President of Medical Devices	5.8yrs	US$5.50m	0.0035% ARS 7.2b
Sabina Ewing	Senior VP of Business & Technology Services and Chief Information Officer	less than a year	sin datos	sin datos
Michael Comilla	Vice President of Investor Relations.	no data	sin datos	sin datos
Erica Battaglia	VP and Chief Ethics & Compliance Officer	no data	sin datos	sin datos
Melissa Brotz	Vice President of Public Affairs & Corporate Marketing	no data	sin datos	sin datos
Christopher Scoggins	Senior Vice President of Commercial Operations	1.8yrs	sin datos	sin datos
Mary Moreland	Executive Vice President of Human Resources	5.3yrs	sin datos	0.0059% ARS 12.1b
Jared Watkin	Executive Vice President of Diabetes Care	9.4yrs	sin datos	0.0042% ARS 8.5b

5.8yrs

Permanencia media

54yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de ABT es experimentado (5.8 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Robert Ford	Chairman of the Board	5yrs	US$23.27m	0.024% ARS 49.1b
Daniel Starks	Independent Director	7.8yrs	US$349.29k	0.39% ARS 788.9b
John Stratton	Independent Director	7.8yrs	US$341.96k	0.00020% ARS 407.8m
Nancy McKinstry	Lead Independent Director	12.9yrs	US$405.96k	0.00027% ARS 550.6m
Michael Roman	Independent Director	3.6yrs	US$337.96k	0% ARS 0
Robert Alpern	Independent Director	16.1yrs	US$441.44k	0% ARS 0
Michael O'Grady	Independent Director	1.6yrs	US$283.96k	0% ARS 0
Michelle Kumbier	Independent Director	6.4yrs	US$331.96k	0.00018% ARS 367.1m
Sally Blount	Independent Director	12.9yrs	US$362.60k	0.00015% ARS 305.9m
Claire Babineaux-Fontenot	Independent Director	2.2yrs	US$354.96k	0% ARS 0
Darren McDew	Independent Director	5.2yrs	US$331.19k	0% ARS 0
Patricia Gonzalez	Independent Director	3.3yrs	US$356.96k	0% ARS 0

5.8yrs

Permanencia media

62yo

Promedio de edad

Junta con experiencia: La junta directiva de ABT se considera experimentada (5.8 años de antigüedad promedio).

Abbott Laboratories Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Abbott Laboratories, Annual General Meeting, Apr 26, 2024

Abbott Laboratories Announces Management Changes, Effective September 1, 2023

Recent updates

Abbott Initiates New Clinical Trial to Improve Outcomes in Patients with Advanced Heart Failure

Abbott Laboratories Provides Earnings Guidance for the Fourth Quarter and Full Year of 2024

Abbott Advances Pulsed Field Ablation Clinical Studies and Launches New Technology to Support Advanced Cardiac Mapping

Abbott Laboratories to Report Q3, 2024 Results on Oct 16, 2024

Abbott Initiates Clinical Study to Evaluate the Use of Its Deep Brain Stimulation System to Manage Severe Depression

Abbott Laboratories Provides Earnings Guidance for the Third-Quarter 2024

Abbott Laboratories(NYSE:ABT) dropped from Russell 1000 Growth-Defensive Index

Abbott Laboratories to Report Q2, 2024 Results on Jul 18, 2024

Purchasers of Certain PediaSure Products in California May Have Their Rights Affected by a Class Action Lawsuit

Abbott Teams Up with the National Association of Community Health Centers to Expand Access to Nutritious Food and Improve Health

Abbott Laboratories Declares Quarterly Common Dividend, Payable on August 15, 2024

Abbott Laboratories Provides Earnings Guidance for the Second Quarter and Full Year of 2024

Abbott Receives FDA Clearance for Whole Blood Rapid Test to Help with Assessment of Concussion at the Patient's Bedside

Abbott Receives FDA Approval for Triclip™, First-Of-Its-Kind Device to Repair Leaky Tricuspid Heart Valve

Abbott Laboratories to Report Q1, 2024 Results on Apr 17, 2024

Abbott Laboratories, Annual General Meeting, Apr 26, 2024

Abbott Announces Real-World Data Show Freestyle Libre Systems and GLP-1 Medicines Work Better Together for People with Type 2 Diabetes

Abbott Declares Quarterly Cash Dividend, Payable on May 15, 2024

FDA Advisory Committee Votes in Favor of Abbott's First-Of-Its-Kind TriClip System to Treat People with a Leaky Tricuspid Heart Valve

Abbott Laboratories Announces the Launch of Its New PROTALITY Brand

Abbott Launches Smallest Rechargeable System with Remote Programming Capabilities to Treat Movement Disorders

Abbott Laboratories Provides Earnings Guidance for the Full Year 2024

Abbott Laboratories Announces First Global Procedures in a Clinical Trial of its Volt™ Pulsed Field Ablation System to Treat Patients with Abnormal Heart Rhythms

Abbott Laboratories Announces Quarterly Dividend Payable on Feb. 15, 2024

Abbott Announces New Late-Breaking Data That Show Advanced Heart Failure Patients Living with its HeartMate 3 Heart Pump

Abbott's Food as Medicine Program Showed Clinically Significant Improvements in Managing Diabetes

Abbott Laboratories Receives FDA Approval for HPV Test to Run on Alinity m, Offering Primary HPV Screening and Assessment of High-Risk Cancer-Causing Types of HPV

Abbott Announces Late-Breaking Data from the LIFE-BTK Clinical Trial Evaluating the Esprit™ BTK Everolimus Eluting Resorbable Scaffold System

Late-Breaking Data Showcase the Benefits of Abbott's Minimally Invasive Devices for People With Leaky Heart Valves

Abbott Laboratories Provides Earnings Guidance for the Full Year 2023

Abbott Laboratories to Report Q3, 2023 Results on Oct 18, 2023

Abbott Laboratories (NYSE:ABT) acquired Bigfoot Biomedical, Inc..

Abbott Declares Quarterly Dividend, Payable on November 15, 2023

Canadian First - Abbott's Tactiflex™ Ablation Catheter Used to Treat Afib

Abbott Laboratories (NYSE:ABT) entered into definitive agreement to acquire Bigfoot Biomedical, Inc.

Abbott Laboratories Provides Earnings Guidance for the Full Year 2023

Abbott Laboratories to Report Q2, 2023 Results on Jul 20, 2023

Abbott Laboratories Announces Management Changes, Effective September 1, 2023

Abbott Declares Quarterly Common Cash Dividend, Payable on August 15, 2023

Abbott Receives FDA Approval for Tactiflex Ablation Catheter for Treatment of Abnormal Heart Rhythm

Abbott Receives FDA Clearance for Assert-IQ™? Insertable Cardiac Monitor to Help Doctors Monitor People's Heart Rhythms Long-Term

Abbott Declares Quarterly Dividend, Payable on May 15, 2023

Abbott Laboratories (NYSE:ABT) entered into a definitive agreement to acquire Cardiovascular Systems, Inc. (NasdaqGS:CSII) for approximately $880 million.

Abbott Laboratories Announces the U.S. Food and Drug Administration Approves Its Proclaim™ XR

Abbott Laboratories Provides Earnings Guidance for the Full-Year 2023

Abbott Receives FDA Approval for Navitor™, a Next-Generation TAVI System Designed to Treat Aortic Stenosis

Abbott and Blood Centers of America Launch First-of-its-Kind Mixed Reality Experience for Use During Blood Donation

Abbott Laboratories to Report Q4, 2022 Results on Jan 25, 2023

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad